Epson America, Inc. today announced that Millstone Medical Outsourcing, a Massachusetts-based provider of medical packaging outsourcing solutions, has selected the Epson ColorWorks® C7500G inkjet label printer to create high-quality color and black-and-white packaging labels for its growing roster of orthopedic and spine customers. As a leading provider of packaging and distribution services, including advanced inspection and validation of medical and clean room device packaging and re-packaging, Millstone Medical Outsourcing required a high-quality label printing solution to address the varying demands of its customers, and the Epson ColorWorks C7500G provided a flexible and easy-to-use option to meet their needs.
“Our customers demand durable, high-quality label and packaging solutions with sometimes very specific details such as barcodes, graphics and meticulous logos – expectations that laser printers, and even legacy two-step inkjet color printing solutions, just couldn’t meet,” said Michael Morrissette, program manager, Millstone Medical Outsourcing. “Using the Epson ColorWorks solution to print on-demand, full color labels has allowed us to better manage our expenses and keep up with the ever-changing medical packaging market. The Epson printer is a product that we can rely on to get the job done for our clients.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7820752-epson-millstone-medical-case-study/
Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi–phased approach, the tests would be developed for Abbott’s i–STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members.1 With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7293951-abbott-u-s-department-of-defense-develop-portable-blood-tests-concussions/
https://nationlife.net/enjoy-eating-without-the-fear-of-choking-with-lifevac-review/
LifeVac is a patented life-saving device that is proven to be the most effective way to help a child or adult during a choking emergency.
Place LifeVac over the mouth and nose to create a seal. The one-way valve prevents air from pushing food or objects downward when pressed. Then simply pull to create a one-way suction to remove the lodged food or object in seconds.
LifeVac gives you peace of mind knowing you’re always prepared and your loved ones are protected – because every second matter.
Recommended by hundreds of doctors and medical professionals around the world. Over 100,000 sold in over 40 countries and counting!
Is your life or your child’s life, worth LESS than 100 bucks to you? This product is absolutely worth every penny. And I’ll be still very happy to have bought it, even if I don’t ever get to use it. I know it is there if I ever need it. This thing is absolutely fantastic. I’ve practiced a few times and from what I saw, it can very well save a life, in those critical few minutes you have, before the person becomes so deprived from oxygen and ultimately dies. Very easy to use. I’m grateful for it.
Always Be Prepared. Get LifeVac Today.
Can’t remember if you locked your front door or left your bedroom window open when you left your house? You’re not alone. Today, Pella® Corporation introduced its new Insynctive® technology app which provides homeowners self-monitored security via their mobile device. Now you can monitor the status of your Pella windows and doors and control motorized between-the-glass blinds and shades in a variety of Pella products, including Architect Series® collections, Designer Series® and entry doors. With the Pella Insynctive app, get real-time push notifications so you know the status of your windows and doors. This new Pella solution creates a way to achieve peace of mind for the 75 percent of Americans who have felt uncertain about whether or not they locked their doors.* Click here to learn more about the Pella Insynctive app works.
To view the multimedia release go to:
https://www.multivu.com/players/English/8334852-pella-windows-new-insynctive-app/
NI (Nasdaq: NATI) today announced VirtualBench, an all-in-one instrument that integrates a mixed-signal oscilloscope, function generator, digital multimeter, programmable DC power supply and digital I/O. Users interact with VirtualBench through software applications that run on PCs or iPads. The device provides the most common functionality affordably and opens up new possibilities for how engineers can use benchtop instruments.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7230751-ni-reshapes-instrumentation-with-software-based-device-virtualbench
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Do you call people out by Clicking accidentally on the touch screen?
Do you have broken/hard pressing power button ?
Do you accidentally call people after you finish talking on Bluetooth headset when the device stays in the pocket?
Most unwanted calls are made after we hung up the call By mistake, because the screen isn\\\\\\\'t lock !!!
This application will help you deal with at least one of the problems.
Before uninstalling app make sure to disable admin permissions in Location
and security > Select device admin > Lock after called
Details:
- The application locks the screen immediately when the call is finished
- There is no need to press the black button to close the phone after
ending a call, simply end the call and put in the pocket
you can set the screen lock after 1 second/ 5 seconds/ 10 seconds / 30 seconds / 1 minute /2 minutes / 5 minutes
Please let me know your device type if the latest version work/didn\\\\\\\'t work on your device
so i can post it for new users/solve your problem
more at:-http://www.lockscreenapp.net/
Continuing its commitment to bringing parents’ technology to the next generation of kids, VTech® today announces the availability of KidiBuzz™, an innovative new hand-held smart device for kids. With quality content and robust features similar to those found in parents’ smartphones, KidiBuzz lets kids play games, watch videos, listen to music, send text messages and more. Already one of the hottest toys for the holiday season, KidiBuzz has earned a place on the influential TTPM Most Wanted List.
“VTech has always strived to adapt adult technology for kids in a smart, engaging way that supports the way they play,” said William To, President, VTech Electronics North America. “KidiBuzz fills a need in the marketplace for kids growing up in the age of smartphones who want to mimic their parents, while addressing the concerns of parents who aren’t ready to commit to the expense and responsibility of a phone and plan.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8140758-vtech-kidibuzz-smart-device-for-kids/
What will it take for drivers to stop texting behind the wheel? Car-buying platform Edmunds.com believes that a gentle reminder from a loved one could do the trick.
Developers of the award-winning Edmunds app recently broke from their usual work to produce “DrivePromise by Edmunds,” a free app that allows Apple Watch and iPhone owners to make and keep a promise to focus on the road while driving. When the device detects that it is in a moving vehicle, it pops up an uploaded photo of a loved one along with a reminder to drive safely. The app keeps count of all of the user’s safe drives to share with friends and family.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7514851-drivepromise-edmunds-app/
ACCU-CHEK Aviva Expert offers people with diabetes a new and easy way to simplify complex calculations to deliver precise insulin dosing advice.
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the ACCU-CHEK® Aviva Expert system, the first and only blood glucose meter system with a built-in insulin calculator to be approved by the U.S. Food and Drug Administration (FDA), is now available by prescription. The device represents a significant advancement in blood glucose meter technology for people with diabetes who take multiple daily insulin injections. The meter’s integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7322751-roche-accu-chek-aviva-expert-blood-glucose-meter-now-available/
Cision, a leading global media intelligence and communications solution provider and portfolio company of GTCR, announced that Kevin Akeroyd has been named global chief executive officer (CEO), effective today. Akeroyd succeeds Peter Granat, who established the company’s position as a global public relations and marketing cloud leader, and will transition to chairman of the Cision Board of Directors.
Akeroyd has more than 25 years of experience in reshaping modern digital, social and mobile marketing globally. Most recently he was general manager and senior vice president at Oracle Marketing Cloud where he orchestrated and executed the industry’s most prolific acquisition strategy, including Marketing Automation, Omni-Channel Campaign Management, Web Personalization, Content Marketing, DMP, Mobile Marketing, Data, and X-Device Orchestration. Under Akeroyd’s leadership, Oracle went from a non-entity to the #2 player in the entire industry in under three years, growing the business in 29 countries globally, and boasting the highest organic growth rate of all the major Marketing Cloud providers rate three years running. Integrating the solutions and the go-to-market, Akeroyd and Oracle created the Enterprise Marketing Platform category and have led it from the onset.
To view the multimedia release go to:
http://www.multivu.com/players/English/7896951-cision-kevin-akeroyd-new-global-ceo/
Abbott announced today that the U.S. Food and Drug Administration has approved the company’s Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States.
Absorb is the only fully dissolving stent approved for the treatment of coronary artery disease, which affects 15 million people in the United States and remains a leading cause of death worldwide, despite decades of therapeutic advances. While stents are traditionally made of metal, Abbott’s Absorb stent is made of a naturally dissolving material, similar to dissolving sutures. Absorb disappears completely in approximately three years, after it has done its job of keeping a clogged artery open and promoting healing of the treated artery segment. By contrast, metal stents are permanent implants that restrict vessel motion for the life of the person treated.
To view the multimedia release go to:
http://www.multivu.com/players/English/7826651-abbott-fda-approval-stent/
